Terms: = Breast cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
221 results:
1. Causal association between complement system FHR-5, CTRP9, and breast carcinoma in situ: a Mendelian randomization study.
Peng YL; Li H; Sun P; Zhang HD; Li D; Wang HB; Zhang L
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2363-2371. PubMed ID: 38567599
[TBL] [Abstract] [Full Text] [Related]
2. Antiproliferative activities of some selected Nigerian medicinal plants against breast, liver, and cervical cancer cells.
Olaleye OO; Kim DH; Spriggs KA
BMC Complement Med Ther; 2024 Mar; 24(1):110. PubMed ID: 38448883
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of BCL-X L , mcl-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in breast cancer.
Saleh T; Al Shboul S; Awad H; El-Sadoni M; Alhesa A; Alsharaiah E; Abu Shahin N; Alotaibi MR; Battah A; Azab B
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):189-199. PubMed ID: 38426376
[TBL] [Abstract] [Full Text] [Related]
4. Structural optimization of siRNA conjugates for albumin binding achieves effective mcl1-directed cancer therapy.
Hoogenboezem EN; Patel SS; Lo JH; Cavnar AB; Babb LM; Francini N; Gbur EF; Patil P; Colazo JM; Michell DL; Sanchez VM; McCune JT; Ma J; DeJulius CR; Lee LH; Rosch JC; Allen RM; Stokes LD; Hill JL; Vickers KC; Cook RS; Duvall CL
Nat Commun; 2024 Feb; 15(1):1581. PubMed ID: 38383524
[TBL] [Abstract] [Full Text] [Related]
5. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
6. Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure.
Nolan J; Buchanan J; Taylor J; Almeida J; Bedenham T; Blair E; Broadgate S; Butler S; Cazeaux A; Craft J; Cranston T; Crawford G; Forrest J; Gabriel J; George E; Gillen D; Haeger A; Hastings Ward J; Hawkes L; Hodgkiss C; Hoffman J; Jones A; Karpe F; Kasperaviciute D; Kovacs E; Leigh S; Limb E; Lloyd-Jani A; Lopez J; Lucassen A; McFarlane C; O'Rourke AW; Pond E; Sherman C; Stewart H; Thomas E; Thomas S; Thomas T; Thomson K; Wakelin H; Walker S; Watson M; Williams E; Ormondroyd E
Genet Med; 2024 Mar; 26(3):101051. PubMed ID: 38131308
[TBL] [Abstract] [Full Text] [Related]
7. Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
Suma S; Suehara Y; Fujisawa M; Abe Y; Hattori K; Makishima K; Sakamoto T; Sawa A; Bando H; Kaji D; Sugio T; Kato K; Akashi K; Matsue K; Carreras J; Nakamura N; Suzuki A; Suzuki Y; Ito K; Shiiba H; Chiba S; Sakata-Yanagimoto M
Leukemia; 2024 Feb; 38(2):340-350. PubMed ID: 38012392
[TBL] [Abstract] [Full Text] [Related]
8. Oncolytic Activity of Canine Distemper Virus in Human Ductal breast Carcinoma Cells.
Jhala D; Nathani N; Joshi M; Patel A; Joshi CG
Oncol Res Treat; 2024; 47(1-2):10-17. PubMed ID: 38008084
[TBL] [Abstract] [Full Text] [Related]
9. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract] [Full Text] [Related]
10. Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers.
McLoughlin EC; Twamley B; O'Brien JE; Hannon Barroeta P; Zisterer DM; Meegan MJ; O'Boyle NM
Bioorg Chem; 2023 Dec; 141():106877. PubMed ID: 37804699
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative breast cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract] [Full Text] [Related]
12. Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase.
Lei J; Pan Y; Gao R; He B; Wang Z; Lei X; Zhang Z; Yang N; Yan M
J Transl Med; 2023 Aug; 21(1):553. PubMed ID: 37592347
[TBL] [Abstract] [Full Text] [Related]
13. 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of mcl-1 expression.
Kuo YH; Lai TC; Chang CH; Hsieh HC; Yang FM; Hu MC
Sci Rep; 2023 Aug; 13(1):12621. PubMed ID: 37537243
[TBL] [Abstract] [Full Text] [Related]
14. Targeting mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy.
Dong S; Matossian MD; Yousefi H; Khosla M; Collins-Burow BM; Burow ME; Alahari SK
Sci Rep; 2023 Jul; 13(1):11843. PubMed ID: 37481672
[TBL] [Abstract] [Full Text] [Related]
15. Aged black garlic extract inhibits the growth of estrogen receptor-positive breast cancer cells by downregulating mcl-1 expression through the ROS-JNK pathway.
Yang Q; Li F; Jia G; Liu R
PLoS One; 2023; 18(6):e0286454. PubMed ID: 37352173
[TBL] [Abstract] [Full Text] [Related]
16. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of surface image guidance and Deep inspiration Breath Hold technique for breast treatments with Halcyon.
Crop F; Laffarguette J; Achag I; Pasquier D; Mirabel X; Cayez R; Lacornerie T
Phys Med; 2023 Apr; 108():102564. PubMed ID: 36989980
[TBL] [Abstract] [Full Text] [Related]
18. A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative breast cancer; Synthesis, Formulation, Characterization and Molecular Studies.
Tawfik NM; Teiama MS; Iskandar SS; Osman A; Hammad SF
Int J Nanomedicine; 2023; 18():1219-1243. PubMed ID: 36937550
[TBL] [Abstract] [Full Text] [Related]
19. Targeted silencing of the mcl-1 gene using multi-layered dendrimer-based nanoconstructs achieves efficient tumor regression in xenografted mice models.
Tambe P; Salve R; Choudhary P; Kumar P; Jadhav S; Paknikar KM; Gajbhiye V
Int J Pharm; 2023 Mar; 634():122659. PubMed ID: 36720446
[TBL] [Abstract] [Full Text] [Related]
20. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE; Peng H; Luo MX; Tan T; Trussart M; Howson LJ; Chua CC; Muttiah C; Brown F; Ritchie ME; Wei AH; Roberts AW; Bryant VL; Anderson MA; Lindeman GJ; Huang DCS; Thijssen R; Gray DHD
Blood Adv; 2023 Jun; 7(12):2733-2745. PubMed ID: 36521105
[TBL] [Abstract] [Full Text] [Related]
[Next]
